Metagenomi Therapeutics Inc (MGX)

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference

EMERYVILLE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

On track for regulatory submission of MGX-001 to advance global clinical program, including investigational new...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

EMERYVILLE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities